| PSA | Prostate-Specific Antigen |
| cfDNA | Cell-free DNA |
| CTCs | Circulating Tumor Cells |
| EVs | Extracellular Vesicles |
| TEPs | Tumor-Educated Platelets |
| ctDNA | Circulating Tumor DNA |
| CRPC | Castration-Resistant Prostate Cancer |
| mCRPC | Metastatic Castration-Resistant Prostate Cancer |
| HRR | Homologous Recombination Repair |
| PARPi | PARP inhibitors |
| EMA | European Medicines Agency |
| SNV | Single Nucleotide Variation |
| INDEL | insertions/deletions |
| CNV | Copy Number Variation |
| NGS | Next-Generation Sequencing |
| MRD | Minimal Residual Disease |
| AR | Androgen Receptor |
| AUC | Area Under the Curve |
| CH | Clonal Hematopoiesis |
| ESMO | European Society for Medical Oncology |
| mHSPC | Metastatic Hormone-Sensitive Prostate Cancer |
| ARSIs | androgen receptor signaling inhibitors |
| IHC | Immunohistochemistry |
| RT-PCR | Real-Time PCR |
| RISH | RNA in situ hybridization |
| MISEV | Minimal Information for Studies of Extracellular Vesicles |